Switching to Abemaciclib May Improve Outcomes After Disease …
Jul 10, 2024 · Real-world evidence suggests that use of abemaciclib after disease progression on a prior CDK4/6 inhibitor may extend progression-free survival, although phase II trials with CDK4/6 inhibitors aside from abemaciclib have generated mixed results.
FDA expands early breast cancer indication for abemaciclib with ...
On March 3, 2023, the Food and Drug Administration (FDA) approved abemaciclib (Verzenio, Eli Lilly and Company) with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant...
Efficacy of abemaciclib plus ET for HR+/HER2–breast cancer
Sep 24, 2024 · Results from the ABIGAIL study showed that the CDK 4/6 inhibitor abemaciclib combined with endocrine therapy (ET) achieved a higher early overall response rate (ORR) at 12 weeks compared to standard chemotherapy as first-line treatment in patients with hormone receptor–positive (HR+)/HER2-negative advanced breast cancer with aggressive ...
Abemaciclib plus endocrine therapy for hormone receptor …
Dec 6, 2022 · Adjuvant abemaciclib reduces the risk of recurrence. The benefit is sustained beyond the completion of treatment with an absolute increase at 4 years, further supporting the use of abemaciclib in patients with high-risk hormone receptor-positive, HER2 …
Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone …
Jan 9, 2024 · Two years of adjuvant abemaciclib combined with endocrine therapy (ET) resulted in a significant improvement in invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS) that persisted beyond the 2-year treatment period in patients with hormone receptor–positive, human epidermal growth factor receptor 2–negative, node ...
FDA approves abemaciclib with endocrine therapy for early breast …
On October 12,2021, the Food and Drug Administration approved abemaciclib (Verzenio,Eli Lilly and Company)with endocrine therapy (tamoxifen or an aromatase inhibitor) for adjuvant treatment of...
Abemaciclib/Fulvestrant Boosts PFS in HR+/HER2– Breast
Jun 2, 2024 · The addition of abemaciclib (Verzenio) to fulvestrant (Faslodex) led to a significant improvement in progression-free survival (PFS) vs fulvestrant alone in patients with hormone...
Abemaciclib as initial therapy for advanced breast cancer
Jun 22, 2021 · In MONARCH 3, continuous dosing of abemaciclib with an aromatase inhibitor (AI) conferred significant clinical benefit to postmenopausal women with HR+, HER2− advanced breast cancer.
MonarchE Update: Benefit of Abemaciclib Increases Over Time
Dec 11, 2022 · Results of a planned interim overall survival analysis of the phase III monarchE trial offer further support for the addition of abemaciclib to adjuvant endocrine therapy for patients with hormone receptor–positive, HER2-negative, node-positive, high-risk breast cancer, according to Stephen R.D. Johnston, MD, PhD, of the Royal Marsden NHS ...
Real-world effectiveness of CDK 4/6 inhibitors in estrogen-positive ...
Jun 20, 2024 · This study aimed to evaluate the real-world effectiveness of abemaciclib, palbociclib, and ribociclib in a Danish context. Additionally, to compare the inhibitors to identify potential endpoint...